HONG KONG, 17 July 2013 – Sihuan Pharmaceutical Holdings Group Ltd. announced that Anaprazole Sodium, a Category 1.1 new drug received the Approval for Clinical Studies from the State Food and Drug Administration (“SFDA”) of the People’s Republic...
Sihuan R&D clinical research centre (based in Beijing) announced that four healthy volunteers (human subjects) were administrated Imigliptin Dihydrochloride at first dosage of 5mg this morning around 8:00 am on 18 Oct 2013, and they all are in good conditions without any observed adverse effects so far.
Sihuan today announced that Pirotinib(哌罗替尼), a Category 1.1 innovative drug which is developed by our innovative drug R&D team applied on 26thSep, was recently accepted by the CFDA(IND filling numbers 1300995 and 1300996).
After receiving approval for Clinical Trial of its self-developed Category 1.1 innovative drug Imigliptin Dihydrochloride, Sihuan Pharmaceutical Group Holdings Limited has established partnership with the preeminent Peking Union Medical College Hospital to conduct the project’s Phase I clinical trial.
The single hexose ganglioside sialic acid four sodium injection produced by Beijing Sihuan Pharm has passed the certification from the Zhongguancun Science Park, and obtained the first batch of self-innovative role model on new tech and new product’s certification.
On August 27, the ceremony for Sihuan Pharmaceutical Holdings Group and Shenyang Pharmaceutical University collaboratively establishing an undergraduate practice teaching base was held in Beijing.